Repligen (RGEN) Competitors $145.93 -4.17 (-2.78%) Closing price 04:00 PM EasternExtended Trading$145.90 -0.03 (-0.02%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGEN vs. TECH, A, DHR, TMO, BIIB, UTHR, INCY, NBIX, EXEL, and BMRNShould you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Bio-Techne (TECH), Agilent Technologies (A), Danaher (DHR), Thermo Fisher Scientific (TMO), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector. Repligen vs. Its Competitors Bio-Techne Agilent Technologies Danaher Thermo Fisher Scientific Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation. Do analysts rate TECH or RGEN? Bio-Techne currently has a consensus price target of $70.17, indicating a potential upside of 18.54%. Repligen has a consensus price target of $169.62, indicating a potential upside of 16.23%. Given Bio-Techne's higher possible upside, analysts clearly believe Bio-Techne is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Techne 1 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.64Repligen 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.73 Which has stronger earnings and valuation, TECH or RGEN? Bio-Techne has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBio-Techne$1.22B7.56$73.40M$0.46128.67Repligen$634.44M12.94-$25.51M-$0.25-583.72 Do institutionals and insiders believe in TECH or RGEN? 99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 1.3% of Bio-Techne shares are held by insiders. Comparatively, 1.2% of Repligen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is TECH or RGEN more profitable? Bio-Techne has a net margin of 6.02% compared to Repligen's net margin of -2.05%. Bio-Techne's return on equity of 13.43% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Bio-Techne6.02% 13.43% 10.32% Repligen -2.05%4.61%3.24% Which has more volatility & risk, TECH or RGEN? Bio-Techne has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Does the media favor TECH or RGEN? In the previous week, Repligen had 9 more articles in the media than Bio-Techne. MarketBeat recorded 15 mentions for Repligen and 6 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.80 beat Repligen's score of 0.63 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBio-Techne beats Repligen on 12 of the 16 factors compared between the two stocks. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition Export to ExcelMetricRepligenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.21B$3.32B$6.10B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-583.7021.5485.6826.86Price / Sales12.94428.10583.23185.42Price / Cash47.8746.3226.3031.10Price / Book4.1410.0613.256.72Net Income-$25.51M-$52.22M$3.30B$276.44M7 Day Performance9.17%5.84%4.70%3.13%1 Month Performance17.16%12.04%8.43%10.21%1 Year Performance6.84%26.13%88.01%40.35% Repligen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen4.6167 of 5 stars$145.93-2.8%$169.62+16.2%+9.8%$8.21B$634.44M-583.701,778Analyst ForecastTECHBio-Techne4.8351 of 5 stars$52.23+0.7%$70.42+34.8%-17.2%$8.07B$1.22B113.553,100Analyst ForecastAAgilent Technologies4.5031 of 5 stars$123.70+0.3%$140.08+13.2%-2.3%$34.98B$6.51B29.0417,900Analyst ForecastDHRDanaher4.98 of 5 stars$185.87+0.6%$245.91+32.3%-21.6%$132.35B$23.88B39.5563,000Positive NewsAnalyst ForecastTMOThermo Fisher Scientific4.8886 of 5 stars$461.95-0.5%$588.35+27.4%-9.0%$175.30B$42.88B26.72125,000Positive NewsAnalyst UpgradeBIIBBiogen4.5582 of 5 stars$138.52+0.8%$182.04+31.4%-17.0%$20.14B$9.68B13.247,605Analyst ForecastUTHRUnited Therapeutics4.331 of 5 stars$424.31-1.9%$449.57+6.0%+27.4%$19.52B$2.88B16.561,305Insider TradeINCYIncyte4.5045 of 5 stars$83.89+1.4%$83.67-0.3%+29.2%$16.15B$4.24B19.072,617NBIXNeurocrine Biosciences4.7866 of 5 stars$140.27-1.2%$161.89+15.4%+22.3%$14.08B$2.36B41.501,800News CoverageEXELExelixis4.8387 of 5 stars$40.57+3.9%$44.42+9.5%+50.1%$10.51B$2.17B19.501,147Positive NewsBMRNBioMarin Pharmaceutical4.9514 of 5 stars$54.02+0.3%$92.60+71.4%-20.0%$10.34B$2.85B16.033,040 Related Companies and Tools Related Companies Bio-Techne Alternatives Agilent Technologies Alternatives Danaher Alternatives Thermo Fisher Scientific Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGEN) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
